High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial
Jean‐Paul Fermand(Sorbonne Université), Jean‐Claude Brouet(Centre National de la Recherche Scientifique), Catherine Boccacio(Hôpital Cochin), Philippe Ravaud(Inserm), Sylvie Chevret(Saint Louis University Hospital), Édouard Pertuiset(Centre Hospitalier René-Dubos), Margaret Macro(Hôpital Cochin), Coralie Bélanger(Hôpital Cochin), Xavier Mariette(Inserm), Véronique Leblond(Sorbonne Université), François Dreyfus(Université Paris-Sud), Marine Diviné(Hôpital Cochin)
Cited by 539
Related Papers
Biologic and clinical significance of cryoglobulins
|The American Journal of Medicine|1974|1.7k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
|The Lancet Oncology|2014|703
Living systematic review: 1. Introduction—the why, what, when, and how
|Journal of Clinical Epidemiology|2017|676